Project Grant R00HL164974
Award Date 8/1/26
Completion Date 6/30/29
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $835,583 under Project Grant R01HL188033 on September 1, 2026, through the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into von Willebrand factor as a driver of trauma-induced thromboinflammation. The project investigates how traumatic injury triggers pathological modifications of von Willebrand factor that propagate neutrophil interactions, netosis, and microvascular...
- The National Institutes of Health National Heart Lung and Blood Institute awarded the University of Pittsburgh $198,728 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sex-specific differences in the remodeling of biopolymer-based tissue-engineered vascular grafts. The research addresses elevated coronary artery bypass graft failure rates in post-menopausal women compared to pre-menopausal women and men by examining vascular smooth muscle...
- The National Heart, Lung, and Blood Institute awarded The Research Foundation For The State University of New York $740,447 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer self-healing, tissue-engineered vascular grafts for use as arteriovenous shunts in hemodialysis patients. The award funds development of self-healing tissue-engineered vessels (SH-TEVs) designed to withstand repeated needle cannulation while maintaining mechanical strength and...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $756,607 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research leveraging nutrient sensing and lysosomal degradative capacity in macrophages as a therapeutic approach to cardiovascular disease. The project addresses atherosclerosis, the underlying cause of myocardial infarction, strokes, and heart failure, by investigating dysfunction in the autophagy-lysosome system...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $767,953 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop biomimetic engineered heart valve leaflets that improve function and tissue remodeling. Work extends through March 31, 2030, and is performed in Pittsburgh, Pennsylvania. The project addresses clinical failures in tissue-engineered heart valves (TEHVs) deployed in pediatric patients, where pulmonary...
- The National Heart, Lung, and Blood Institute awarded New York University $836,736 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial mechanosensing of circulatory flow in health and disease. The project will examine how endothelial cells lining blood and lymphatic vessels respond to fluid flow forces, with focus on the roles of PLXND1 (a transmembrane semaphorin receptor) and KLF2 (a transcription factor) in endothelial responses to...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $1,088,692 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on interorganellar calcium signaling in health and disease. The award funds basic research examining how calcium signaling across the plasma membrane, endoplasmic reticulum, mitochondria, and lysosomes generates localized calcium microdomains that regulate transcriptional and metabolic programs...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $758,972 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Project Grant R01HL187185) to investigate overlooked socioeconomic determinants of adolescent cardiovascular health, specifically examining how family wealth, assets, and debts influence cardiovascular risk factors in youth. The research addresses the gap in existing scholarship by focusing on wealth as an economic...
- The National Heart, Lung, and Blood Institute awarded Carnegie Mellon University $249,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect lung spatial-biological niches in early fibrogenesis. The research project aims to spatially profile and recapitulate disease-specific microenvironments that drive early fibrogenesis in interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis. The work addresses a clinical need to elucidate...
- The National Heart, Lung, and Blood Institute (NHLBI) of the Department of Health and Human Services awarded $1,545,864 to the University of Pittsburgh on August 7, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund Project Grant R01HL187347, an investigation into immune-mediated lung repair following early life respiratory viral infection. The research defines mechanisms of viral lower respiratory tract infection (LRTI)–driven lung damage and repair in neonates, with...